Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients - Wikidata - wikimedia - TriplyDB

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

http://www.wikidata.org/entity/Q33644305

about

Tumor antigen-specific monoclonal antibodies and induction of T-cell immunity Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.Generation of a canine anti-EGFR (ErbB-1) antibody for passive immunotherapy in dog cancer patients.Resistance to HER2-targeted therapies: a potential role for FOXM1.CD4+CD25(high), CD8+CD28- cells and thyroid autoantibodies in breast cancer patients.Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumab Anti-GD2 mAb and Vorinostat synergize in the treatment of neuroblastoma Trastuzumab as a preoperative monotherapy does not inhibit HER2 downstream signaling in HER2-positive breast cancer.IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM).Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.Porphyrin modified trastuzumab improves efficacy of HER2 targeted photodynamic therapy of gastric cancer.Effect of trastuzumab interchain disulfide bond cleavage on Fcγ receptor binding and antibody-dependent tumour cell phagocytosis.Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar In vivo and in vitro activity of an immunoglobulin Fc fragment (Fcab) with engineered Her-2/neu binding sites.An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma.Potentiation of Natural Killer Cells for Cancer Immunotherapy: A Review of Literature FcγRIIA and IIIA polymorphisms predict clinical outcome of trastuzumab-treated metastatic gastric cancer.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions.Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas.Fc-mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models.A Chimeric Antibody against ACKR3/CXCR7 in Combination with TMZ Activates Immune Responses and Extends Survival in Mouse GBM Models.A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ.Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses.Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.Pertuzumab, trastuzumab and eribulin mesylate therapy for previously treated advanced HER2-positive breast cancer: a feasibility study with analysis of biomarkers.Tumor immunotherapy: New aspects of natural killer cells.The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2.IL-6 augments IL-4-induced polarization of primary human macrophages through synergy of STAT3, STAT6 and BATF transcription factors

P2860

Q27009908-DBC6962F-46DB-40E3-832E-F356992B9563 Q33913839-FE2E218B-59F5-4528-B828-C0F6546C5520 Q34240076-DD79F431-EE88-4637-868E-80243516C6B8 Q34955355-83CF2572-AFC3-47DC-ACFC-E49339C02CE6 Q35631779-B9CE3B29-EDA8-4A1F-8CAA-6FDBF7066C08 Q36139709-A97FBFFB-E687-430B-9BEF-D37F98A6E412 Q36539682-08E9F923-C0B4-4D5A-93F3-37E30DFFB4DB Q36729467-4F62C08E-CC66-43A0-891B-B84F7EC035C2 Q37010668-7DFE5025-4E00-4A0F-840F-23D2B6EFFD34 Q37022365-27FE06CB-CF29-4000-BB59-F332BBEC9FFE Q37078946-49767582-300C-4638-99C1-A06CFD15B60B Q37205832-F25A4318-71C2-434B-9F64-A1C3352DE0BD Q37709365-1CAC0008-8116-4D3C-8DF9-CF417F5B95BD Q38262066-4DCF68B0-6FDA-41AC-A7EB-26F163E03155 Q38286163-8F0652CB-FCA4-4937-B987-8432FF74B31F Q38699434-5481107D-3605-45EF-A46E-9A12492AEC94 Q38845280-7666C535-152C-40FA-8383-837FEE279FD8 Q38896842-257B9227-EE92-41BC-AEE3-4E661DC089AF Q38906179-6E3B73F8-8A5D-4056-BCEF-B092AD73B77E Q38997358-3B128B70-E0C7-4B11-A970-81FB6FC5CE32 Q39231967-A0F5FEA4-24BD-4403-A6BA-DA0186C85669 Q41619501-3A815B82-BD85-4203-A1F4-105A232B5218 Q42965942-A735C4A5-9A92-4154-B405-A2ECD3BF24C5 Q47221234-D6E1B88C-5771-432E-9A08-37B1A9BD5E0D Q48263702-609C0C76-7AC3-4954-B23D-E3A953E04918 Q49672464-37D74982-2897-4D3E-8B6F-15705C8FD0EB Q49832498-9F555F94-6BB1-47FD-A7AD-F74095115E9A Q51731320-30905B42-30B3-4F31-8483-8A8F11CE2B6D Q52597562-ED12EB78-4D8E-46D4-8E10-C4651767EBF2 Q52684751-04E72331-99CC-44A6-82A5-9CEE68A4F9C3 Q52716381-2F16E14E-210F-4347-AD38-315DDCBFC6A8 Q55078620-59DBA43C-6610-4E2B-BEB9-E91D4EB8F530 Q55107050-6EABA046-662C-49B5-8070-9DDAD70FEFB2 Q55183005-852F7A06-4F64-4ECC-9E9D-239AA184EBD9 Q57138348-86B29619-0ED1-4DCC-9621-ADA6AED5F11B

P2860

Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients

http://www.wikidata.org/entity/Q33644305

description

2013 nî lūn-bûn

@nan

2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Trastuzumab mediates antibody- ...... ER2/neu breast cancer patients

@ast

Trastuzumab mediates antibody- ...... ER2/neu breast cancer patients

@en

type

label

Trastuzumab mediates antibody- ...... ER2/neu breast cancer patients

@ast

Trastuzumab mediates antibody- ...... ER2/neu breast cancer patients

@en

prefLabel

Trastuzumab mediates antibody- ...... ER2/neu breast cancer patients

@ast

Trastuzumab mediates antibody- ...... ER2/neu breast cancer patients

@en

P1433

Q33644305-609666C6-1D0C-4BA1-9497-1E3765BDA858

P1476

Q33644305-FEA313DE-58A8-4E07-9A27-EC043F111BF8

P2093

Q33644305-5F699838-DE05-4BAB-AD40-311F0090BC79

Q33644305-7534E53C-6F8A-4D86-8306-366A0129D7EB

Q33644305-89F4A0CA-CD90-4E71-AF0A-561EB0097490

Q33644305-9A9399DF-47D2-432F-A618-0AC26B29BC7D

Q33644305-DBA58EE6-860A-4ED2-BE7E-15F3B003FA8B

P2860

Q33644305-0C78A2CB-452D-4C4B-9BCB-1FF51DCF8D47

Q33644305-0CBC021F-F409-4E0A-99A9-14A84A15515F

Q33644305-0E689139-A396-4B89-BC30-3EBEA69E0ACA

Q33644305-10CE07B6-FD78-41A7-8152-95E32C005C22

Q33644305-1116A7F0-73FF-4326-8B3A-BA509B9D3148

Q33644305-17010458-EC2D-4FAF-8321-40696227B081

Q33644305-19BE7B11-967C-464D-80F5-4EEB1BFC0EDC

Q33644305-1ADF44AE-0CC8-4E03-BC1F-E6472F2009B4

Q33644305-2170ADB1-F5CD-41DF-BFDB-1C94A4E7F1D3

Q33644305-222CFDBB-6E45-44DC-BC4A-8FD5AB19CD8E

P2888

Q33644305-13A4CCDF-C731-41A6-BC5D-3B1FB35C72CD

P304

Q33644305-F1F1DF34-D2E8-4DBF-A526-C1EFCA0282BF

P31

Q33644305-BA0B46B6-3B2D-4006-97AF-6078FAF74E53

P356

Q33644305-1C1C6FF9-BCBE-4FD6-B099-75926E0DDA5F

P478

Q33644305-60EA3125-D413-4F86-A59C-22DC906B5265

P50

Q33644305-607395A6-9326-4C5E-865F-7FD0219F5B4F

Q33644305-6D5A4278-7783-4FDC-A264-DE392E30952C

Q33644305-976A4B3B-6097-409F-84AA-921D74D1393B

Q33644305-E9AB540E-6B2E-48FD-B485-0475E4E4D7F7

P577

Q33644305-F9BABD6B-6C76-4069-B529-7D35DB836143

P5875

Q33644305-9719050B-F7E1-471C-BC6D-3A9DC933500E

P6179

Q33644305-B5E1F491-8975-4D4A-8598-E304DC73F150

P698

Q33644305-D3B05F01-669A-4850-84F3-04FEBA371B30

P921

Q33644305-30D82999-FC58-47DF-ACB9-FECF6EE6954C

Q33644305-5E4720B1-BCEC-48D9-B9E9-F5AB001C363C

Q33644305-A9222859-2901-42D3-AAF4-F8E9EC1C339F

P932

Q33644305-F94C7F54-B7D3-413B-AEB9-547BE3FB8D74

P356

1479-5876-11-307

P1433

Journal of Translational Medicine

P1476

Trastuzumab mediates antibody- ...... ER2/neu breast cancer patients

@en

P2093

Branka Petricevic

http://www.w3.org/2001/XMLSchema#string

Guenther Steger

http://www.w3.org/2001/XMLSchema#string

Josef Singer

http://www.w3.org/2001/XMLSchema#string

Monika Sachet

http://www.w3.org/2001/XMLSchema#string

Rupert Bartsch

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

Trastuzumab--mechanism of action and use in clinical practice

CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.

Age-dependent alterations of monocyte subsets and monocyte-related chemokine pathways in healthy adults

Expression profile of FcgammaRIIb on leukocytes and its dysregulation in systemic lupus erythematosus.

Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials.

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

P2888

1479-5876-11-307

P304

307

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1479-5876-11-307

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Erika Jensen-Jarolim

Johannes Laengle

Michael Bergmann

P577

2013-12-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259315750

http://www.w3.org/2001/XMLSchema#string

P6179

1034898772

http://www.w3.org/2001/XMLSchema#string

P698

24330813

http://www.w3.org/2001/XMLSchema#string

P921

P932

4029549

http://www.w3.org/2001/XMLSchema#string